37 (Most people with Medicaid are enrolled in managed care plans, rather than fee-for-service Medicaid.) 38 Again, as with the categories described above, coverage of a drug for weight loss is different from coverage of the same drug to treat diabetes or reduce cardiovascular risk
More than 250 clinicians signed a letter (PDF) to the Senate HELP Committee expressing concern about the lack of patient access to novel non-insulin diabetes and weight loss medications due to exorbitant prices set by manufacturers
Type 2 diabetes treatments in 2025 go beyond insulin therapy, with emphasis on oral GLP-1s, SGLT2 inhibitors, and once-weekly insulin formulations
Its FDA approval underscores its safety and efficacy as a weight-loss treatment
The CareGLP platform is described as SOC2 and HIPAA-compliant
Dosing adjustments are made based on both lab results and clinical symptoms